LARIMAR THERAPEUTICS, INC. Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid
LARIMAR THERAPEUTICS, INC. (LRMR) had Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid of $1.29 million as of 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid · last filed 2020-05-07
- 2020-03-31: Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid $1.29M.
- 2019-12-31: Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid $1.19M.
- 2019-09-30: Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid $1.07M.
- 2019-06-30: Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid $945.00K.
| Period end | Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid |
|---|---|
| 2020-03-31 | $1.29M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.19M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $1.07M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $945.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $799.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $640.00K 10-K · filed 2020-03-05 |
| 2016-09-30 | $394.00K 10-Q · filed 2016-11-09 |
| 2015-12-31 | $306.00K 10-Q · filed 2016-11-09 |
| 2015-06-30 | $227.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $181.00K 10-Q · filed 2015-05-14 |
| 2014-12-31 | $137.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |